Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAN | American Academy of Neurology |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AMCP | Academy of Managed Care Pharmacy |
| ANCOVA | Analysis of covariance |
| ANZCTR | Australian New Zealand Clinical Trials Registry |
| AOHD | Adult-onset Huntington's disease |
| AS | Advanced stage |
| ASO | Antisense oligonucleotide |
| BIA | Budget impact analysis |
| BLA | Biologics License Application |
| C-SSRS | Columbia-Suicide Severity Rating Scale |
| CAG | Cytosine-adenine-guanine trinucleotide repeat |
| CAP | CAG-age product |
| CEPAC | Comparative Effectiveness Public Advisory Council |
| CHMP | Committee for Medicinal Products for Human Use |
| CI | Confidence interval |
| CN | Caudate nucleus |
| COE | Center of Excellence |
| CRD | Centre for Rare Disorders (Oslo University Hospital) |
| CSF | Cerebrospinal fluid |
| CTA | Clinical Trial Application |
| cUHDRS | Composite Unified Huntington's Disease Rating Scale |
| DCL | Diagnostic confidence level |
| DGN | German Neurological Society (Deutsche Gesellschaft für Neurologie) |
| DMT | Disease-modifying treatment |
| DSMB | Data Safety Monitoring Board |
| ECG | Electrocardiogram |
| EHDN | European Huntington's Disease Network |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol 5-dimension questionnaire |
| ES | Early stage |
| FDA | US Food and Drug Administration |
| GeM-HD | Genetic Modifiers of Huntington's Disease Consortium |
| GINA | Genetic Information Nondiscrimination Act |
| GWA | Genome-wide association |
| GWAS | Genome-wide association study |
| H-QoL-I | Huntington Quality of Life Instrument |
| HCDM | Health care decision-maker |
| HD | Huntington's disease |
| HD-ISS | Huntington's Disease Integrated Staging System |
| HDBOI | Huntington's Disease Burden of Illness study |
| HDQLIFE | Huntington Disease Health-related Quality of Life measurement system |
| HDSA | Huntington's Disease Society of America |
| HE | Highly expanded (CAG repeat subgroup) |
| HR | Hazard ratio |
| HREC | Human Research Ethics Committee |
| HRQoL | Health-related quality of life |
| HRU | Healthcare resource utilization |
| HSG | Huntington Study Group |
| HTT | Huntingtin gene or protein |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| IND | Investigational New Drug application |
| IQR | Interquartile range |
| IS | Independence Scale |
| ISPOR | Professional Society for Health Economics and Outcomes Research (formerly International Society for Pharmacoeconomics and Outcomes Research) |
| JHD | Juvenile Huntington's disease |
| JoHD | Juvenile-onset Huntington's disease |
| KM | Kaplan-Meier |
| Kp,uu | Unbound CSF-to-unbound plasma concentration ratio |
| LE | Low expansion (CAG repeat subgroup) |
| LoHD | Late-onset Huntington's disease |
| LS | Least squares |
| LTC | Long-term care |
| MAA | Marketing Authorisation Application |
| MAD | Multiple ascending dose |
| MDS | International Parkinson and Movement Disorder Society; movement disorders specialist |
| MDT | Multidisciplinary team |
| mHTT | Mutant huntingtin protein |
| MMR | DNA mismatch repair |
| MRI | Magnetic resonance imaging |
| MS | Mid stage |
| MSH3 | MutS homolog 3 |
| NCDR | Norwegian Cause of Death Registry |
| NfL | Neurofilament light chain |
| NHS | National Health Service |
| OLE | Open-label extension |
| PFD | Prefunctional decline |
| PK | Pharmacokinetics |
| PMPM | Per member per month |
| PMS1 | PMS1 homolog 1, mismatch repair system component (postmeiotic segregation increased 1) |
| PPPM | Per patient per month |
| PREDICT-HD | Neurobiological Predictors of Huntington's Disease study |
| PTMPM | Per treated member per month |
| PwHD | People with Huntington's disease |
| PY | Person-years |
| QALY | Quality-adjusted life year |
| QD | Once daily |
| RCT | Randomized controlled trial |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SDMT | Symbol Digit Modalities Test |
| SE | Standard error |
| SF-6D | Short-Form 6-Dimension |
| SF1, SF2 | Shoulson and Fahn stage 1, stage 2 |
| SNF | Skilled nursing facility |
| SNP | Single nucleotide polymorphism |
| SNRI | Serotonin-norepinephrine reuptake inhibitor |
| SoC | Standard of care |
| SSRI | Selective serotonin reuptake inhibitor |
| SWRT | Stroop Word Reading Test |
| TEAE | Treatment-emergent adverse event |
| TFC | Total Functional Capacity |
| TGA | Therapeutic Goods Administration (Australia) |
| tHTT | Total huntingtin protein |
| TMS | Total Motor Score |
| TRACK-HD | TRACK-HD observational study |
| TTO | Time trade-off |
| UHDRS | Unified Huntington's Disease Rating Scale |
| UK | United Kingdom |
| US | United States |
| VMAT2 | Vesicular monoamine transporter 2 |
| vMRI | Volumetric magnetic resonance imaging |
| WT | Wild-type |
| WTP | Willingness to pay |